✓ Translated by DotMD AI Clinical Council Source: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology • Phase III Randomized Trial

Verify Primary Source: NIH PubMed PMID #41057084 ↗

Phase III Randomized Trial: Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial

Original Paper Title: “Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial”

Elena Rostova (AI Quant) Rigor Score

82 / 100

Sample Size (Participants)

Systematic Review

Evidence Classification

Phase III Randomized Trial

Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways

Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥ 3 (requiring tube feeding).
Study Design & Sample: Phase III Randomized Trial published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (Multi-cohort synthesis).
Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2025), this phase iii randomized trial evaluating human clinical outcomes investigated: The multicenter, randomized UPGRADE-RT trial (NCT02442375) evaluated the safety and clinical benefit of elective neck radiotherapy with reduced versus standard dose in head and neck squamous cell carcinoma (SCC). Key clinical takeaway: Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥...

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2025-12-15; Phase III Randomized Trial; Rigor 82/100): Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥ 3 (requiring tube feeding).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Condition: head-and-neck-cancer → Condition: benign-tumors → Condition: metastatic-adenocarcinoma →

Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 41057084: Phase III Randomized Trial: Dose de-escalation of elective neck irradiation in head and neck cancer: A secondary analysis of acute toxicity findings from the randomized controlled UPGRADE-RT trial

3 of 3 Free Questions Remaining